Abstract Purpose: The number of studies that evaluate treatment margins for high grade gliomas (HGG) are limited. We hypothesize that patients with HGG who are treated with a gross tumor volume (GTV) to planning tumor volume (PTV) expansion of ≤1 cm will have progression-free survival (PFS) and overall survival (OS) rates similar to those treated in accordance with standard protocols by the Radiation Therapy Oncology Group or European Organisation for Research and Treatment of Cancer. Furthermore, the PFS and OS of subgroups within the study population will have equivalent survival outcomes with GTV1-to-PTV1 margins of 1.0 cm and 0.4 cm. Methods and materials: Treatment plans and outcomes for patients with pathologically confirmed HGG were analyzed (n = 267). Survival (PFS and OS) was calculated from the time of the first radiation treatment and a χ 2 test or Fisher exact test was used to calculate the associations between margin size and patient characteristics. Survival was estimated using Kaplan-Meier and compared using the log-rank test. All analyses were performed on the univariate level.
Introduction
An estimated 24,790 new cases of primary malignant brain tumors were expected to be diagnosed in the United States in 2016. Approximately 50% of gliomas are glioblastomas (GBM) with 12,120 new cases predicted. 1 Glioblastoma is a diagnosis with a 5%, 5-year survival rate. 2 Despite significant advances in radiation therapy, neurosurgery, neuro-imaging, and chemotherapy for HGG, prognosis remains bleak with median progression-free survival (PFS) times for GBM and anaplastic glioma (AG) of 6.9 and 36 months, respectively, and overall survival (OS) times of 14.6 and 56.4 months, respectively. [3] [4] [5] Radiation therapy (RT) became the standard of care for HGG after randomized trials in the 1970s demonstrated improved survival outcomes. 6, 7 Although initial studies suggested a need for whole brain RT (WBRT), subsequent trials with improved imaging showed no advantage of WBRT over partial-brain irradiation. 8 These studies also revealed that the predominant pattern of treatment failure for HGG was within 2 to 3 cm of the primary tumor. 7 Small studies in the 1980s documented tumors to be histologically present 2 cm to 3 cm from the primary tumor volume on computed tomography (CT) scans and infiltrating into the edema volume on magnetic resonance imaging (MRI). 5, 9 On the basis of these data, the most standard margins used for conformal irradiation delivered to a target volume (defined by edema volume for the initial field and T1 gadoliniumenhanced volume for boost field) and now most often identified on MRI, is surrounded by a 2 cm to 3 cm margin as outlined by Stupp et al., Radiation Therapy Oncology Group (RTOG) 0525, RTOG 0825, and other standard treatment protocols. 3, 10, 11 In addition to this margin, a set-up error margin is added on the basis of individual institutions' set-up paradigm. Evidence-based guidelines show scant literature evaluating alternative margins. 12 Radiation therapy to the brain is associated with significant acute and late neurotoxic sequelae that are positively correlated with a higher treatment dose and larger treatment volume. Advances in image guided RT (IGRT) and stereotactic RT and improved image quality support reducing the margin needed, and some radiation oncologists have adopted smaller treatment margins for HGG in an effort to reduce these toxicities and improve patients' quality of life. However, despite this rationale, there is a dearth of published data that study the specific deviations from standard protocols. 13 Radiation therapy treatment margins that were used at our institution between 2006 and 2017 are considerably smaller than those defined in the current RTOG and European Organisation for Research and Treatment of Cancer (EORTC) treatment protocols. They have been consistently applied because of a well-developed, frameless, stereotactic experience that reduces set-up inaccuracy to 0.5 mm and because of the availability of highresolution MRI (0.6 mm × 0.6mm × 1.0 mm voxel size) within the radiation oncology department. Using smaller margins minimizes irradiation-induced damage of normal brain tissue. Our standard practice uses noninvasive daily stereotactic guidance or IGRT for daily localization unless the patient is unable to cooperate, which is rare.
We evaluated the outcomes for patients who were treated with smaller margins (PFS and OS) compared with patients who were treated with the standard approximate 2 cm to 3 cm margins that were adopted by the conventional protocols (RTOG and EORTC). Furthermore, one of our staff physicians generally uses 0.4 cm margins added to the edema and T1-enhanced target volumes while another physician generally uses 1.0 cm margins for these expansions. We evaluated the outcomes of patients who were treated by these two physicians.
Methods and materials

Patient population
This study was approved by our institutional review board. Data from all adult patients who received definitive RT for HGG between 2006 and 2017 were reviewed. We included patients for analysis who met the following criteria: 1) age ≥18 years, 2) pathologically confirmed World Health Organization Grade III AG or grade IV GBM, and 3) received definitive RT (defined as a dose of ≥45 Gy).
This review resulted in 267 evaluable cases. Several patients included in this study were treated in accordance with protocols that had specific radiation therapy guidelines such as RTOG 0525, RTOG 0825, NewLink Genetics 2102 (indoximod and temozolomide [TMZ] for TMZ-refractory malignant brain tumors), and North Central Cancer Treatment Group N0877 (dasatinib vs placebo combined with standard chemoradiation therapy) that specify standard margin requirements (n = 8). 3, 10, [14] [15] [16] These patients were excluded for the analysis of reduced tumor margins. An investigator-initiated trial of intravenous ascorbate used institutional-specific margins for planning (n = 12) and was included in the margin analysis.
All treatment plans and margins were reviewed in the treatment planning system (Philips Healthcare, Andover, MA). Patient demographic and outcome data were retrieved from the electronic medical records (EPIC, Verona, WI) including imaging and follow up for progression and survival.
Treatment
Patients who were treated for HGG between 2006 and 2017 most commonly received RT doses and chemotherapy regimens as outlined in the Stupp et al. and RTOG 0825 protocols. 10, 11 Therapy for HGG includes maximal safe resection followed by RT to 61.2 Gy at 1.8 Gy per fraction with concurrent TMZ starting within 6 weeks after surgery.
The 61.2 Gy dose is split into an initial 45 Gy dose in 25 fractions followed by a 16.2 Gy boost in 9 fractions. The initial simulation consists of the formation of a custom biteplate and mask for imaging and daily stereotactic positioning. 17, 18 A contrast-enhanced, high-resolution CT is acquired with 0.6 × 0.6 × 1.0 mm voxel size. Volumetric T2, fluidattenuated inversion recovery (FLAIR), and T1 gadoliniumenhanced MRI are acquired on a 3T MRI simulator with 1 mm voxel resolution and the thermoplastic mask in place. Image fusion is accomplished in the treatment planning system prior to the manual contouring of the treatment volumes. Preoperative imaging is also fused to aid in tumor cavity and areas at risk of identification for targeting.
Typically, the initial 45 Gy is delivered to the edema volume as defined by T2 or FLAIR imaging and consistent with the RTOG definition. An expansion of 0.4 cm or 1.0 cm is then applied to define a planning target volume (PTV) 1. Barriers to tumor growth such as dura and bone are considered and margins reduced accordingly within the limit of daily setup. This is inconsistent with RTOG, which expands the edema volume by 2 cm to 2.5 cm and adds an additional 0.3 cm to 0.5 cm for setup to define this PTV1. The boost 16.2 Gy is delivered to a cone-down volume that encompasses the enhancing tumor volume or resection cavity as outlined on the T1 gadolinium-enhanced scan. This volume is also expanded by 0.4 cm or 1.0 cm to create the PTV2 while similarly considering barriers to tumor growth. This also differs from the RTOG protocol, which adds 2 cm to this enhancing tumor volume or cavity plus 0.3 cm to 0.5 cm for setup to create the PTV2.
All RT plans were normalized such that at least 95% of PTV1 and PTV2 received the prescribed dose. The majority of the plans used intensity modulated techniques with daily stereotactic positioning as described.
Follow up
Postradiation imaging begins approximately 30 days after completion of RT and then is scheduled after every 2 cycles of TMZ (approximately every 2 months). Patients are scheduled to receive a minimum of 6 cycles of TMZ with some patients electing to continue TMZ after this initial treatment. Although this has not been shown to improve long-term outcomes in HGG, the decision for this additional adjuvant therapy was most often made prior to data availability to the contrary.
Analysis
Survival (PFS and OS) was calculated from the time of the first RT fraction. The date of imaging after RT that demonstrated radiographic progression confirmed by the attending radiation oncologist was defined as the date of the first progression. If death occurred from suspected progression without imaging confirmation, the date of death was used as the date of tumor progression. The date of death was determined using electronic medical records and online obituary sources.
Associations between margin size and patient characteristics were calculated using the χ 2 or Fisher exact test for small sample sizes where appropriate and statistical testing was performed using SAS version 9.4 (SAS Institute, Cary, NC). Survival probabilities were estimated and plotted using the Kaplan-Meier method. OS is defined as the date of death or last follow-up and PFS as the time until recurrence or the date of the last follow-up visit. All testing is performed on the univariate level and unadjusted for multiple comparisons due to the exploratory nature of the project. Differences between the survival curves were compared using the log-rank test. All statistical testing is 2-sided and assessed for significance at the 5% level.
Results
Patient characteristics
A total of 267 patients met the inclusion criteria from January 2006 to May 2017 ( Smaller margins do not change glioma outcomes
Treatment margin had no effect on outcome. The 1.0 cm margin subgroup (n = 212) showed median PFS and OS times of 10.7 and 19.1 months, respectively, and the 0.4 cm margin subgroup (n = 55) had times of 10.2 and 19.3 months (Fig. 1) . There was no effect of margin size within either the GBM or AG group. In comparison with historical standard treatment with 2 cm to 3 cm margins, there was not a significant difference in outcomes.
All patients received some type of surgery and 108 of 267 patients (40.4%) had gross total resection, 82 patients (30.7%) subtotal resection, and 77 patients (28.8 %) a biopsy only. A total of 259 patients (97%) patients received a total dose of 59.4 to 61.2 Gy, and 8 patients (3%) received a total dose of 45 to 59.3 Gy. Daily stereotactic localization was used in addition to a facemask for 195 patients (73%) and the remaining 72 patients (27%) had a facemask only, generally complemented with daily cone beam CT for alignment. The margins were adjusted when localization accuracy was not done using stereotactic techniques or daily image guidance.
In addition, 243 patients (91.0%) received TMZ chemotherapy as part of the treatment regimen, of whom 223 patients (83.5%) were treated with concurrent chemotherapy and RT and 214 patients (80.1%) received adjuvant chemotherapy after radiation. Patient and treatment characteristics are summarized in Tables 1 through 5. As found in previous studies, sex, grade III histology, type of surgery, chemotherapy, and age are significant predictors of PFS and OS at the univariate level. Margin size is not a significant predictor of PFS or OS between the subgroups (0.4 vs 1.0 cm margins) in this study (Fig. 1) , nor is there a difference in PFS or OS when comparing data from our patients who were treated with reduced margins (≤1.0 cm) to those from historical reports. This review provides data that patients who were treated with ≤1.0 cm median margins did not have a difference in survival compared with patients who were treated with 2 to 3 cm margins. Moreover, patients who were treated with 0.4 cm margins demonstrate no survival difference. The study did not address differences in toxicity between the treatment groups, although a theoretic benefit of smaller volumes was noted. Similarly, recurrences were reported as within the treatment field in the vast majority of cases with no preponderance of marginal or distant failures noted in any group. A detailed analysis of these recurrence patterns was beyond the scope of this report.
Discussion
High-grade gliomas remain associated with an extremely poor prognosis. Multiple clinical trials over decades have evaluated varying fractionation, dose, and radiation sensitizers, yet none resulted in significant changes to local recurrence patterns or outcomes. [19] [20] [21] With advances in technology (both imaging and positioning methods) leading to the improved precision of radiation delivery and the potential to better identify tumor-involved regions, the trend in RT has been to decrease treatment margins and, hence, treatment volumes. This decrease has potential benefit in HGG treatment where tumors are surrounded by critical neural structures but less than certainly identified. Unfortunately, alternative treatment margins have not been carefully investigated. 10 Our approach with high-resolution MRI combined with stereotactic or image guided daily localization is now readily available at most academic medical centers as well as many community practices and enables better investigations of target definition and margins.
Clinical trials for HGG still typically use 2 to 3 cm expansion margins as outlined in RTOG or EORTC protocols. Both groups define the ultimate target as the surgical tumor bed plus the residual-enhancing tumor. The EORTC employs a single-phase technique where this target is expanded by 2 cm to 3cm and 5 mm to 7mm is also added for daily positioning (PTV) and treated to 60 Gy in 30 fractions. For RTOG, the sum of the T1-enhancing target and peritumoral edema (defined on T2 or FLAIR images) defines an initial target volume. This is expanded 2 cm (or 2.5 cm if no edema is present) to create PTV1, which is treated to 46 Gy in 23 fractions. This is Figure 1 Progression-free and overall survival by margin size Smaller margins do not change glioma outcomes followed by a cone-down boost dose of 14 Gy in 7 fractions that is delivered to the gross residual tumor or tumor cavity on T1 contrast-enhanced imaging plus a margin of 2.3 to 2.5 cm. These guidelines are inconsistent with the smaller (≤1 cm) margins that are employed at our institution.
Several studies report that TMZ therapy does not alter HGG treatment failure patterns. 22 The same has been shown with the use of smaller margins (0.5 cm clinical target volume margins plus 0.5 cm PTV expansion) and intensity modulated RT. 20, 23 Evidence in support of 2 to 3 cm margin standards in national protocols is limited. A brief search of the peer-reviewed literature returned papers that reported patient outcomes after treatment with smaller margins. Three institutions treated patients with HGG in accordance with the Adult Brain Tumor Consortium (ABTC) guidelines, which expand the contrast-enhancing T1 volume or resection cavity by 0.5 cm to create a clinical target volume, which is further expanded by 0.3 to 0.5 cm for the PTV.
Investigators at Emory University evaluated the patterns of tumor progression when using ABTC guidelines (n = 43) 24 and found that 93% of recurrences were in field, 5% were marginal, and only 2% were distant. Investigators from Wake Forest University evaluated outcomes with varied expansion margins (n = 145) and found no significant differences in patterns of failure, PFS, or OS between different margin groups (0.5 cm: n = 29; 1 cm: n = 78; 1-2 cm: n = 38). 20 The University of Alabama reviewed outcomes of patients (n = 95) who were treated per the ABTC guidelines and that reported 81% of patients experienced in-field failure and only 6% experienced marginal progression. 25 Although these studies used ABTC margins, which are smaller than RTOG and EORTC margins, the total margin in these studies is 0.8 to 1.0 cm, which is significantly larger than our institution's 0.4 cm median margin subgroup (n = 55).
Increasing treatment margin size can considerably increase the volume of brain tissue that is irradiated. For example, treating a spherical tumor with a 5 cm radius with a 0.4 cm margin results in irradiation of a volume of 136.0 cm 3 of tissue. In contrast, a 2 to 3 cm margin results in an irradiation of 913.2 to 1621.1 cm 3 , which represents a 7-to 12-fold increase in irradiated volume compared with the 0.4 cm margin.
Advances in MRI may also improve the quality of tumor targeting and potentially reduce or increase the size of targets using a range of techniques. Diffusion weighted imaging along with apparent diffusion coefficient have been associated with increased cellularity and potentially with areas of increased tumor infiltration. Perfusion imaging with dynamic susceptibility contrast maps may identify areas of increased blood flow associated with tumor. MRI spectroscopy is also evolving rapidly to enable larger volume acquisitions with more facile processing that may make these methods more accessible for tumor targeting on the basis of chemical metabolites. All this may substantially change our approach to margins, particularly when coupled with precise daily localization methods.
The effects of radiation on local and systemic immune function are worth considering. Grossman et al. conducted a prospective study and observed the effects of immunosuppression in patients with HGG who were treated with radiation and TMZ. 26 The results suggest that median survival time is correlated with CD4 suppression. Furthermore, CD4 suppression was associated with death from tumor progression. Increased exposure of circulating blood volume to radiation has been shown to lead to a CD4 T-cell deficit, which can persist after RT due to the disruption of the compensatory cytokine response. Although we did not measure immune relevant endpoints in this study, one could reasonably hypothesize that reduced volumes irradiated could reduce lymphopenia severity and hence improve anti-tumor immune response. 27 A review by Wernicke et al. discusses the importance of the radiation-induced antitumor T-effector response. 28 Two types of T-cells are at play: Tumor-infiltrating lymphocytes (TILs), which suppress the innate antitumor response, and T-effector cells, which can be induced against tumor cells. Most lymphocytes are extremely radiosensitive with an early beneficial radiation effect of elimination of TILs. Radiation also increases the release of tumor neo-antigens that induce a T-effector response. Unfortunately, like TILs, T-effector cells are easily killed by radiation. Fractionated treatment over long periods of time and increased radiation treatment volume will cause increased toxicity to T-effector cells, which decreases the body's ability to attack tumor cells.
Preclinical studies have shown improved survival in glioma mouse models treated with T-cell boosting therapies plus radiation versus radiation alone. 29, 30 The significance of TILs has also been studied in patients. Han et al. showed that a high level of CD4+ TILs combined with a low level of CD8+ TILs was associated with an unfavorable prognosis in patients with GBM. The use of checkpoint inhibitors and other cancer immunotherapies is currently under evaluation in GBM and may add to a rationale for smaller local fields that enable effector cell activation. 31, 32 We recognize that these potential benefits are speculative but they do add to the rationale to consider smaller fields as an alternative.
Potential limitations of this study include the potential selection bias that is associated with any retrospective design as well as confounding variables on OS, such as the rigor or nature of salvage therapies. Molecular data such as O6-methylguanine-DNA methyltransferase (MGMT), 1p/ 19q deletion, and isocitrate dehydrogenase-1 status was not performed for the majority of the time period in the study and thus not included; therefore, whether or not these factors alter the impact of margins is not clear. Brandes et al. reported on the patterns of failure of GBM using RTOG margins and found that 85% of patients with unmethylated MGMT had failure within field or marginally compared with 58% of patients with methylated MGMT. 33 The present lack of data prevents the evaluation of molecular traits as confounding factors in the analysis of planning margins and survival. A recent clinical trial suggested that our patient population mimics norms for MGMT and isocitrate dehydrogenase-1 status. 34 In addition, this retrospective study was not designed to perform a detailed analysis of histologic subtypes of anaplastic gliomas such as oligodendroglial versus astrocytic variants, potential benefits of reduced toxicity with smaller fields, or a detailed analysis of treatment failures in reference to the delivered dose distributions that were registered to the recurrence scans. Although these would be interesting additions and the results potentially informative, the retrospective nature and overall goal to correlate outcomes with margins was a valuable initial finding that may spur additional investigations into the impact of treatment volume and margin on management of HGG.
With 259 patients evaluable for outcomes after treatment with reduced treatment margins, this review represents the largest study to date to evaluate the effect of smaller radiation-planning margins on patient survival. A review of literature suggests that this is the first study to evaluate patients who were treated with total PTV margins of 0.4 cm (n = 55). The results suggest that smaller RT margins in the treatment of high-grade gliomas do not impact survival outcomes. These data, coupled with the lack of an evidenced-based standard margin, survival data from ABTC studies, potential rationale from immune mediators of the radiation-induced antitumor response, and reduced neurotoxicity that is associated with smaller RT fields, suggest the need for further studies to reevaluate the treatment margin guidelines for high-grade gliomas.
Conclusions
Using smaller-than-standard margin RT for high-grade gliomas results in PFS and OS times that are consistent with those reported in the existing literature and historical controls. Using margins as small as 0.4 cm instead of the 2 to 3 cm used in conventional protocols significantly reduces the volume of normal brain tissue that is radiated during treatment. Future studies could potentially study the effect of smaller margins on anti-tumor T-effector response.
